Advertisement
UK markets closed

  • FTSE 100

    8,139.83
    +60.97 (+0.75%)
     

  • FTSE 250

    19,824.16
    +222.18 (+1.13%)
     

  • AIM

    755.28
    +2.16 (+0.29%)
     

  • GBP/EUR

    1.1679
    +0.0022 (+0.19%)
     

  • GBP/USD

    1.2494
    -0.0017 (-0.13%)
     

  • Bitcoin GBP

    50,421.89
    -1,001.11 (-1.95%)
     

  • CMC Crypto 200

    1,304.48
    -92.06 (-6.59%)
     

  • S&P 500

    5,099.96
    +51.54 (+1.02%)
     

  • DOW

    38,239.66
    +153.86 (+0.40%)
     

  • CRUDE OIL

    83.66
    +0.09 (+0.11%)
     

  • GOLD FUTURES

    2,349.60
    +7.10 (+0.30%)
     

  • NIKKEI 225

    37,934.76
    +306.28 (+0.81%)
     

  • HANG SENG

    17,651.15
    +366.61 (+2.12%)
     

  • DAX

    18,161.01
    +243.73 (+1.36%)
     

  • CAC 40

    8,088.24
    +71.59 (+0.89%)
     

GLOBAL NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET FORECAST 2021-2028

ReportLinker
·3-min read

KEY FINDINGS The global non-alcoholic steatohepatitis (NASH) biomarker market is projected to grow with a CAGR of 20. 65%, over the forecast period of 2021 to 2028. The market growth is mainly accredited to factors, such as, the rising NASH affected population, the surging awareness associated with non-alcoholic fatty liver disease, the increasing occurrence of chronic diseases, and the increasing prevalence of obesity and diabetes.

New York, Jan. 28, 2021 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "GLOBAL NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET FORECAST 2021-2028" - https://www.reportlinker.com/p06010867/?utm_source=GNW


MARKET INSIGHTS
Non-alcoholic steatohepatitis (NASH), a highly destructive form of non-alcoholic fatty liver disease (NAFLD), often develops into more severe disorders, like hepatocellular carcinoma and cirrhosis.As a result, NASH is projected to surpass the hepatitis C virus infection and become the leading cause of liver transplantation, worldwide, over the upcoming decade.

As these diseases progress, the liver experiences fibrosis and scarring, ultimately leading to cirrhosis. Liver fibrosis is likely to result in permanent organ damage, progress to hepatocellular carcinoma, and liver failure.
Obesity is a well-recognized epidemic, globally.The increasing incidence and prevalence of obesity have surged drastically, over the last ten years.

For instance, according to the World Health Organization (WHO) 2020 report, more than 1.9 billion adults, aged 18 and older, were overweight in 2016. Out of which, 650 million individuals were obese. In addition, 38 million children below the age of 5 were overweight or obese in 2019. On the other hand, as per the 2020 Diabetes Research and Clinical Practice report, the worldwide prevalence of diabetes in 2019, was nearly 9.3%, and is expected to rise to 10.2% by 2030.

REGIONAL INSIGHTS
The global non-alcoholic steatohepatitis (NASH) biomarker market growth is evaluated by assessing the Asia Pacific, North America, Europe, and the rest of the world.The Asia Pacific is set to be the fastest-growing market over the forecast period.

The region’s market growth is attributed to the enhanced healthcare infrastructure, improved economic conditions, and rising healthcare awareness in developing countries like China and India.

COMPETITIVE INSIGHTS
The industrial rivalry is anticipated to be moderate, owing to the unavailability of treatment.Besides, key market players focus on research, development, and partnerships, in order to introduce products into the market.

Some of the leading companies operating in the market are, Merck & Co, AstraZeneca, Novartis AG, Pfizer Inc, etc.

Our report offerings include:
• Explore key findings of the overall market
• Strategic breakdown of market dynamics (Drivers, Restraints, Opportunities, Challenges)
• Market forecasts for a minimum of 9 years, along with 3 years of historical data for all segments, sub-segments, and regions
• Market Segmentation cater to a thorough assessment of key segments with their market estimations
• Geographical Analysis: Assessments of the mentioned regions and country-level segments with their market share
• Key analytics: Porter’s Five Forces Analysis, Vendor Landscape, Opportunity Matrix, Key Buying Criteria, etc.
• Competitive landscape is the theoretical explanation of the key companies based on factors, market share, etc.
• Company profiling: A detailed company overview, product/services offered, SCOT analysis, and recent strategic developments

Companies mentioned
1. ALLERGAN PLC (ACQUIRED BY ABBVIE)
2. ASTRAZENECA
3. BRISTOL -MYERS SQUIBB COMPANY
4. GENFIT SA
5. GILEAD SCIENCES INC
6. MADRIGAL PHARMACEUTICALS
7. MERCK & CO
8. NOVARTIS AG
9. NOVO NORDISK
10. PFIZER INC
11. SIEMENS HEALTHINEERS
12. VIKING THERAPEUTICS
13. ZYDUS CADILA
Read the full report: https://www.reportlinker.com/p06010867/?utm_source=GNW

About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________

CONTACT: Clare: clare@reportlinker.com US: (339)-368-6001 Intl: +1 339-368-6001